{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:22Z","timestamp":1793338402564,"version":"4.5.0"},"reference-count":262,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115360","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:34:43Z","timestamp":1789572883000},"page":"115360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Tumor-homing peptides in precision oncology"],"prefix":"10.1016","volume":"399","author":[{"given":"Guojun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Kheira","family":"Derkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Senhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Karoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Poyet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115360_bb0005","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1461-5347(99)00211-4","article-title":"Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?","volume":"2","author":"Duncan","year":"1999","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.jconrel.2026.115360_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214636","article-title":"Enhanced permeability and retention (EPR) effect: advances in nanomedicine for improved tumor targeting","volume":"181","author":"Khan","year":"2026","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2026.115360_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.102915","article-title":"Enhanced permeability and retention effect: a key facilitator for solid tumor targeting by nanoparticles","volume":"39","author":"Shinde","year":"2022","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jconrel.2026.115360_bb0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0055","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115360_bb0060","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115360_bb0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115360_bb0070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115360_bb0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0080","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.05.008","article-title":"Perspectives on the past, present, and future of cancer nanomedicine","volume":"130","author":"Youn","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115360_bb0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115360_bb0105","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S584604","article-title":"Nanobody-based drug delivery: emerging strategies for targeted cancer therapy","volume":"21","author":"Ghosh","year":"2026","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115360_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70319","article-title":"Nanobodies: pioneering next-generation tools in modern medicine","volume":"87","author":"Folorunsho","year":"2026","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17474086.2020.1819230","article-title":"A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Gomez-Segui","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.01.045","article-title":"Research trends in the use of nanobodies for cancer therapy","volume":"381","author":"Hou","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2025.130884","article-title":"Nanobody-based imaging: advancing precision in molecular diagnostics","volume":"1870","author":"Eftekhari","year":"2026","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.jconrel.2026.115360_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1697","article-title":"Nanobody-A versatile tool for cancer diagnosis and therapeutics","volume":"13","author":"Liu","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115368","article-title":"Nanobodies targeting cytokines for the amelioration of autoimmune diseases","volume":"164","author":"Vijayandran","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189284","article-title":"Challenges and opportunities in single-domain antibody-based tumor immunotherapy","volume":"1880","author":"Xi","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00432-023-05519-y","article-title":"Molecular probes targeting HER2 PET\/CT and their application in advanced breast cancer","volume":"150","author":"Gao","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0155","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ymthe.2025.10.043","article-title":"Nanobody-enhanced T cell cancer immunotherapy: advancing precision medicine","volume":"34","author":"Boisgard","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0160","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5628","article-title":"Application of nanobody-based CAR-T in tumor immunotherapy (review)","volume":"56","author":"Liu","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0165","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2174\/0929867321666140217122100","article-title":"Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics","volume":"21","author":"Gautam","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0170","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/cas.14909","article-title":"Tumor-homing peptide and its utility for advanced cancer medicine","volume":"112","author":"Kondo","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2012.02.002","article-title":"Peptides for cell-selective drug delivery","volume":"33","author":"Svensen","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2026.115360_bb0185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115360_bb0190","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","article-title":"Peptide therapeutics: targeting the undruggable space","volume":"94","author":"Tsomaia","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0195","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2174\/1381612829666230201121353","article-title":"Production technology and functionality of bioactive peptides","volume":"29","author":"Wen","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115360_bb0200","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tibs.2018.11.008","article-title":"Hitting undruggable targets: viewing stabilized peptide development through the Lens of quantitative systems pharmacology","volume":"44","author":"Atangcho","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082091","article-title":"Membrane-active peptides and their potential biomedical application","volume":"15","author":"Gostaviceanu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115360_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biopha.2017.05.054","article-title":"Vascular-homing peptides for cancer therapy","volume":"92","author":"Lu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115360_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2017.09.016","article-title":"Overcoming key biological barriers to cancer drug delivery and efficacy","volume":"267","author":"Kim","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0225","article-title":"Cancer nanomedicine: emerging strategies and therapeutic potentials","volume":"28","author":"Xu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb0230","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1039\/D5NR04462F","article-title":"Factors governing tumor penetration of nanomedicines: intrinsic and extrinsic determinants","volume":"18","author":"Shin","year":"2026","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115360_bb0235","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3892\/mmr.2017.6419","article-title":"iRGD as a tumor-penetrating peptide for cancer therapy (review)","volume":"15","author":"Yin","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0240","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115360_bb0245","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1021\/acsabm.3c00711","article-title":"Advances in peptide-decorated targeted drug delivery: exploring therapeutic potential and nanocarrier strategies","volume":"7","author":"Buddhiraju","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2026.115360_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118482","article-title":"Recent advances in peptide-drug conjugates as anticancer agents","volume":"304","author":"Feng","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70119","article-title":"Peptide therapeutics for solid tumors: functional classes, AI-enhanced discovery and clinical advances","volume":"32","author":"Liang","year":"2026","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115360_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125555","article-title":"Focus on therapeutic peptides and their delivery","volume":"675","author":"Rosson","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115360_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119491","article-title":"Just how prevalent are peptide therapeutic products? A critical review","volume":"587","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115360_bb0275","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug conjugate-based anticancer therapy - current status and perspectives","volume":"552","author":"Yang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.115360_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040481","article-title":"Peptide-based strategies for targeted tumor treatment and imaging","volume":"13","author":"Ayo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115360_bb0290","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acsbiomaterials.5c00218","article-title":"Empowering healthcare with phage display technology","volume":"11","author":"Lyu","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2026.115360_bb0295","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/biot.201500458","article-title":"Advance in phage display technology for bioanalysis","volume":"11","author":"Tan","year":"2016","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2026.115360_bb0300","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138161210790963788","article-title":"Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications","volume":"16","author":"Brown","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115360_bb0305","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/molecules16010857","article-title":"Peptide phage display as a tool for drug discovery: targeting membrane receptors","volume":"16","author":"Molek","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb0310","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115360_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/v17070975","article-title":"A beautiful bind: phage display and the search for cell-selective peptides","volume":"17","author":"Bakhshinejad","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.115360_bb0320","doi-asserted-by":"crossref","first-page":"20725","DOI":"10.1038\/s41598-022-25257-4","article-title":"Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides","volume":"12","author":"Mansour","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1019749504418","article-title":"Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library","volume":"21","author":"Karasseva","year":"2002","journal-title":"J. Protein Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/0008-5472.CAN-05-2748","article-title":"Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries","volume":"66","author":"Kolonin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0335","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/380364a0","article-title":"Organ targeting in vivo using phage display peptide libraries","volume":"380","author":"Pasqualini","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115360_bb0340","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115360_bb0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-396962-0.00002-1","article-title":"Mapping of vascular ZIP codes by phage display","volume":"503","author":"Teesalu","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1196\/annals.1413.003","article-title":"Peptide targeting of tumor lymph vessels","volume":"1131","author":"Laakkonen","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0076-6879(08)03004-8","article-title":"Chapter 4. Screening phage-display peptide libraries for vascular targeted peptides","volume":"445","author":"Trepel","year":"2008","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0360","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ejca.2007.02.006","article-title":"Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors","volume":"43","author":"Balestrieri","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0365","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.addr.2017.05.006","article-title":"Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment","volume":"119","author":"David","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0370","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0375","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s12033-024-01195-6","article-title":"Phage display as a medium for target therapy based drug discovery, review and update","volume":"67","author":"Jahandar-Lashaki","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0380","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/17460441.2024.2367023","article-title":"Phage display technology and its impact in the discovery of novel protein-based drugs","volume":"19","author":"Hutchings","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115360_bb0385","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13238-019-0639-7","article-title":"Phage display screening of therapeutic peptide for cancer targeting and therapy","volume":"10","author":"Saw","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.jconrel.2026.115360_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tips.2018.12.005","article-title":"Phage display: an overview in context to drug discovery","volume":"40","author":"Mimmi","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0395","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/srep01607","article-title":"Computational approach for designing tumor homing peptides","volume":"3","author":"Sharma","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0400","article-title":"TumorHoPe2: an updated database for tumor homing peptides","author":"Kashyap","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.jconrel.2026.115360_bb0405","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/acsptsci.5c00241","article-title":"Advancing cancer-targeted Nanotherapies with tumor homing peptides","volume":"8","author":"Rocchi","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.compbiolchem.2019.05.008","article-title":"THPep: a machine learning-based approach for predicting tumor homing peptides","volume":"80","author":"Shoombuatong","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105700","article-title":"NEPTUNE: a novel computational approach for accurate and large-scale identification of tumor homing peptides","volume":"148","author":"Charoenkwan","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210348","article-title":"StackTHPred: identifying tumor-homing peptides through GBDT-based feature selection with stacking ensemble architecture","volume":"24","author":"Guan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0425","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00726-024-03422-5","article-title":"LLM4THP: a computing tool to identify tumor homing peptides by molecular and sequence representation of large language model based on two-layer ensemble model strategy","volume":"56","author":"Yang","year":"2024","journal-title":"Amino Acids"},{"key":"10.1016\/j.jconrel.2026.115360_bb0430","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae275","article-title":"Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides","volume":"25","author":"Goles","year":"2024","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.jconrel.2026.115360_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27092660","article-title":"Review on the QM\/MM methodologies and their application to metalloproteins","volume":"27","author":"Tzeliou","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16233979","article-title":"In silico design of peptide inhibitors targeting HER2 for lung cancer therapy","volume":"16","author":"Alkhatabi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115360_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbag188","article-title":"Generative design and validation of therapeutic peptides for glioblastoma based on a potential target ATP5A","volume":"27","author":"Qian","year":"2026","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.jconrel.2026.115360_bb0450","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/path.1472","article-title":"Integrins in regulation of tissue development and function","volume":"201","author":"Danen","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0455","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115360_bb0460","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.tcb.2004.10.005","article-title":"Integrins: versatile integrators of extracellular signals","volume":"14","author":"ffrench-Constant","year":"2004","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0470","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006478","article-title":"alphaV integrins in angiogenesis and cancer","volume":"1","author":"Weis","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0485","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.2174\/138161205774580787","article-title":"Vascular homing peptides with cell-penetrating properties","volume":"11","author":"Ruoslahti","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.115360_bb0490","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115360_bb0495","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2013.00216","article-title":"Tumor-penetrating peptides","volume":"3","author":"Teesalu","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0500","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M111.331140","article-title":"Structural basis for selective vascular endothelial growth factor-a (VEGF-A) binding to neuropilin-1","volume":"287","author":"Parker","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0505","doi-asserted-by":"crossref","first-page":"29120","DOI":"10.1074\/jbc.R115.687327","article-title":"Neuropilin functions as an essential cell surface receptor","volume":"290","author":"Guo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0510","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112457118","article-title":"A widespread viral entry mechanism: the C-end rule motif-neuropilin receptor interaction","volume":"118","author":"Balistreri","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115360_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70630","article-title":"Neuropilin-1 as a neuroinflammatory entry factor for SARS-CoV-2 is attenuated in vaccinated COVID-19 patients: a case-control study","volume":"8","author":"Hosseini","year":"2025","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0520","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1038\/s41598-024-78068-0","article-title":"Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-1","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0525","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0530","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1038\/ncomms5904","article-title":"An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability","volume":"5","author":"Pang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115360_bb0535","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jcb.10140","article-title":"VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding","volume":"85","author":"Soker","year":"2002","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0540","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/path.2182","article-title":"Neuropilins in physiological and pathological angiogenesis","volume":"212","author":"Staton","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0545","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0550","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0555","doi-asserted-by":"crossref","first-page":"36466","DOI":"10.1074\/jbc.M604812200","article-title":"Spontaneous formation of L-isoaspartate and gain of function in fibronectin","volume":"281","author":"Curnis","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0560","doi-asserted-by":"crossref","first-page":"19757","DOI":"10.1074\/jbc.M710273200","article-title":"Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin","volume":"283","author":"Spitaleri","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0565","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2174\/138920111796117373","article-title":"Tumor vasculature targeting through NGR peptide-based drug delivery systems","volume":"12","author":"Corti","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0570","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115360_bb0575","doi-asserted-by":"crossref","first-page":"47891","DOI":"10.1074\/jbc.M207500200","article-title":"Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif","volume":"277","author":"Colombo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0580","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acs.bioconjchem.6b00136","article-title":"NGR tumor-homing peptides: structural requirements for effective APN (CD13) targeting","volume":"27","author":"Graziadio","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0585","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/pr.58.1.8","article-title":"Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery","volume":"58","author":"Khalil","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0590","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/bs.acr.2015.04.004","article-title":"Scavenger receptors: emerging roles in cancer biology and immunology","volume":"128","author":"Yu","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0595","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2004.10.018","article-title":"Cationic TAT peptide transduction domain enters cells by macropinocytosis","volume":"102","author":"Kaplan","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb0600","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0605","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.18632\/oncotarget.3401","article-title":"Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion","volume":"6","author":"Roselli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115360_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188429","article-title":"Balancing neurotrophin pathway and sortilin function: its role in human disease","volume":"1874","author":"Al-Yozbaki","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0615","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.ajpath.2020.05.018","article-title":"The membrane protein Sortilin can be targeted to inhibit pancreatic cancer cell invasion","volume":"190","author":"Gao","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0620","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1093\/emboj\/20.9.2180","article-title":"The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein","volume":"20","author":"Nielsen","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2026.115360_bb0625","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2008.06.021","article-title":"Sortilin mediates the lysosomal targeting of cathepsins D and H","volume":"373","author":"Canuel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115360_bb0630","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1111\/cas.15086","article-title":"TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer","volume":"112","author":"Demeule","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081877","article-title":"The peptide-drug conjugate TH1902: a new Sortilin receptor-mediated cancer therapeutic against ovarian and endometrial cancers","volume":"14","author":"Currie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115360_bb0640","article-title":"Sudocetaxel zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing","volume":"15","author":"Demeule","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091910","article-title":"The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human SORT1-positive ovarian and triple-negative breast cancer stem-like cells","volume":"14","author":"Demeule","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115360_bb0650","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0655","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115360_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121970","article-title":"Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges","volume":"329","author":"Rezaei","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0665","article-title":"CXCR4-targeted radiopharmaceuticals for the imaging and therapy of malignant tumors","volume":"28","author":"Yu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb0670","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ird3.46","article-title":"Clinical applications of fibroblast activation protein-targeted theranostics in oncologic and nononcologic disease: current status and future directions","volume":"1","author":"Fu","year":"2023","journal-title":"iRADIOLOGY"},{"key":"10.1016\/j.jconrel.2026.115360_bb0675","article-title":"Therapeutic prospects of nectin-4 in cancer: applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0680","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5273","article-title":"Role of Nectin-4 protein in cancer (review)","volume":"59","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0685","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The anti-nectin 4: a promising tumor cells target. A systematic review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073200","article-title":"The significance of Nectin family proteins in various cancerogenous processes","volume":"26","author":"Romanczyk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0695","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1349-7006.2003.tb01499.x","article-title":"Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization","volume":"94","author":"Takai","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb0700","doi-asserted-by":"crossref","first-page":"14337","DOI":"10.1021\/acs.jmedchem.2c00065","article-title":"Discovery of BT8009: a Nectin-4 targeting bicycle toxin conjugate for the treatment of Cancer","volume":"65","author":"Mudd","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0705","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"BT8009; a Nectin-4 targeting bicycle toxin conjugate for treatment of solid tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0710","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00259-025-07609-0","article-title":"A pilot study of nectin-4-targeted radioligand [(68)Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [(18)F]-FDG","volume":"53","author":"Jiang","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115360_bb0715","doi-asserted-by":"crossref","first-page":"40324","DOI":"10.1038\/s41598-025-24074-9","article-title":"Synthesis of a novel specific nectin-4 tumor-targeted peptide optical molecular probe and its preliminary study in lung cancer","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0720","doi-asserted-by":"crossref","DOI":"10.1097\/MOU.0000000000001388","article-title":"The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents","author":"Lee","year":"2026","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0725","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1200\/JCO-25-00559","article-title":"First-in-human, phase I\/II dose escalation and expansion study of Zelenectide Pevedotin in patients with advanced solid tumors: results from monotherapy dose escalation","volume":"43","author":"Baldini","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0730","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2025.2510669","article-title":"Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer","volume":"34","author":"Cigliola","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2026.115360_bb0735","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17576180.2025.2452837","article-title":"The validation and clinical bioanalysis of the bicycle(R) toxin conjugate zelenectide pevedotin in human plasma","volume":"17","author":"Tweed","year":"2025","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jconrel.2026.115360_bb0740","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clim.2006.06.006","article-title":"The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0745","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0750","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1073\/pnas.78.7.4515","article-title":"Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin","volume":"78","author":"Sutherland","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115360_bb0755","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1357-2725(99)00070-9","article-title":"The transferrin receptor: role in health and disease","volume":"31","author":"Ponka","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0760","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0092-8674(04)00130-8","article-title":"Structure of the human transferrin receptor-transferrin complex","volume":"116","author":"Cheng","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115360_bb0765","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1046\/j.1432-1327.2001.02073.x","article-title":"Receptor mediated uptake of peptides that bind the human transferrin receptor","volume":"268","author":"Lee","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0770","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2008.08.031","article-title":"Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide","volume":"274","author":"Oh","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.115360_bb0775","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2013.07.019","article-title":"T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting","volume":"454","author":"Kuang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115360_bb0780","doi-asserted-by":"crossref","first-page":"17932","DOI":"10.1038\/s41598-018-35938-8","article-title":"HAI peptide and backbone analogs-validation and enhancement of biostability and bioactivity of BBB shuttles","volume":"8","author":"Arranz-Gibert","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115360_bb0785","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI44798","article-title":"Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma","volume":"121","author":"Staquicini","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115360_bb0790","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1021\/acs.molpharmaceut.5b00222","article-title":"Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an Iron-mimic peptide targeting transferrin\/transferrin receptor complex","volume":"12","author":"Kang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115360_bb0795","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17132070","article-title":"Novel strategies and therapeutic advances for bladder cancer","volume":"17","author":"Ehrlich","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115360_bb0800","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4155\/bio-2020-0256","article-title":"Development of a LC-MS\/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a phase I study","volume":"13","author":"Gowland","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jconrel.2026.115360_bb0805","doi-asserted-by":"crossref","first-page":"18519","DOI":"10.1021\/acs.jmedchem.5c01304","article-title":"Development and evaluation of [(68)Ga]Ga-DOTA-BT1718: a novel imaging agent targeting MT1-MMP for malignant tumor diagnosis","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0810","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bjp.2008.260","article-title":"Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2","volume":"155","author":"Regina","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0815","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s11095-009-9964-5","article-title":"Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer","volume":"26","author":"Thomas","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0820","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and design of peptides as a new drug delivery system for the brain","volume":"324","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0825","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2011.427","article-title":"Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1","volume":"105","author":"Bertrand","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0830","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-016-3972-z","article-title":"ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment","volume":"160","author":"O\u2019Sullivan","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2026.115360_bb0835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gendis.2017.01.004","article-title":"Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)","volume":"4","author":"Li","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/j.jconrel.2026.115360_bb0840","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0845","article-title":"Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma","volume":"6","author":"Dmello","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.jconrel.2026.115360_bb0850","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060833","article-title":"A phase II, multicenter, single-arm study of Mipsagargin (G-202) as a second-line therapy following Sorafenib for adult patients with progressive advanced hepatocellular carcinoma","volume":"11","author":"Mahalingam","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115360_bb0855","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/cbt.4.1.1505","article-title":"The SERCA pump as a therapeutic target: making a \u201csmart bomb\u201d for prostate cancer","volume":"4","author":"Denmeade","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0860","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003886","article-title":"Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy","volume":"4","author":"Denmeade","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0865","first-page":"1445","article-title":"Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells","volume":"2","author":"Pinto","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0870","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0875","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0880","first-page":"987","article-title":"Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb0885","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920905424","article-title":"An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)","volume":"12","author":"Wang","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0890","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.21037\/jgo-22-727","article-title":"Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)","volume":"13","author":"Wang","year":"2022","journal-title":"J. Gastrointest Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0895","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0900","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2026.115360_bb0905","doi-asserted-by":"crossref","DOI":"10.3390\/nano15221733","article-title":"Nanotechnology driven innovations in modern pharmaceutics: therapeutics, imaging, and regeneration","volume":"15","author":"Parvin","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2026.115360_bb0910","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11030229","article-title":"The 35th anniversary of the discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery-personal remarks and future prospects","volume":"11","author":"Maeda","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb0920","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115360_bb0925","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nnano.2012.207","article-title":"Biomolecular coronas provide the biological identity of nanosized materials","volume":"7","author":"Monopoli","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0930","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9090325","article-title":"Targeted therapeutic nanoparticles: an immense promise to fight against cancer","volume":"2017","author":"Jahan","year":"2017","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115360_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24020351","article-title":"Peptide-based drug-delivery systems in biotechnological applications: recent advances and perspectives","volume":"24","author":"Tesauro","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb0940","article-title":"Advances in peptide-based drug delivery systems","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.115360_bb0945","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115360_bb0950","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2026.115360_bb0955","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","article-title":"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors","volume":"11","author":"Kurzrock","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020525","article-title":"Multimeric RGD-based strategies for selective drug delivery to tumor tissues","volume":"15","author":"Cossu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115360_bb0965","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3389\/fphar.2019.01450","article-title":"From synthesis to characterization of site-selective PEGylated proteins","volume":"10","author":"Belen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0970","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115360_bb0975","doi-asserted-by":"crossref","first-page":"17047","DOI":"10.1073\/pnas.1304987110","article-title":"Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety","volume":"110","author":"Zhu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115360_bb0980","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119233","article-title":"Zwitterionic Janus dendrimer with distinct functional disparity for enhanced protein delivery","volume":"215","author":"Wang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115360_bb0990","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1039\/C1CS15233E","article-title":"Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment","volume":"41","author":"Walkey","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb0995","doi-asserted-by":"crossref","first-page":"11422","DOI":"10.1039\/D3NR01768K","article-title":"Significance and implications of nanoparticle-biological corona fingerprints in diagnosis, prognosis, and therapeutics for diverse disorders","volume":"15","author":"Ren","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115360_bb1000","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1021\/nn406018q","article-title":"Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles","volume":"8","author":"Walkey","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115360_bb1005","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1021\/ja9608757","article-title":"Cyclic RGD peptides containing \u03b2-turn mimetics","volume":"118","author":"Haubner","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.115360_bb1010","doi-asserted-by":"crossref","first-page":"25213","DOI":"10.1021\/acs.jmedchem.5c02209","article-title":"Dually decorated palmitate-containing lipid nanoparticles for the targeted delivery of siRNAs against HER2 and Hsp27 in HER2(+) breast cancer","volume":"68","author":"Medina","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2533\/chimia.2021.500","article-title":"Radiolabeled peptides for cancer imaging and therapy: from bench-to-bedside","volume":"75","author":"Mansi","year":"2021","journal-title":"Chimia (Aarau)."},{"key":"10.1016\/j.jconrel.2026.115360_bb1020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem. Biomed. Imag."},{"key":"10.1016\/j.jconrel.2026.115360_bb1025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1035","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-12-0374","article-title":"Integrin alphavbeta3-targeted IRDye 800CW near-infrared imaging of glioblastoma","volume":"18","author":"Huang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb1040","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and Gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/rg.352140164","article-title":"Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation","volume":"35","author":"Hofman","year":"2015","journal-title":"Radiographics"},{"key":"10.1016\/j.jconrel.2026.115360_bb1050","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067550","article-title":"Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors","volume":"8","author":"Sugiyama","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115360_bb1065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.jconrel.2026.115360_bb1070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb1075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/psc.2836","article-title":"Advances in Fmoc solid-phase peptide synthesis","volume":"22","author":"Behrendt","year":"2016","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb1080","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1021\/acs.joc.3c01494","article-title":"Process mass intensity (PMI): a holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis","volume":"89","author":"Kekessie","year":"2024","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1085","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The current state of peptide drug discovery: back to the future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1090","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nbt1340","article-title":"Renal clearance of quantum dots","volume":"25","author":"Choi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1095","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115360_bb1100","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1021\/jm4011675","article-title":"Hydrocarbon-stapled peptides: principles, practice, and progress","volume":"57","author":"Walensky","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1105","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.563030","article-title":"D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.vascn.2010.02.010","article-title":"To protect peptide pharmaceuticals against peptidases","volume":"61","author":"Rink","year":"2010","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2026.115360_bb1115","doi-asserted-by":"crossref","DOI":"10.3390\/biom8010004","article-title":"Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo","volume":"8","author":"Kumar","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.115360_bb1120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11010-009-0172-8","article-title":"The effect of C-terminal amidation on the efficacy and selectivity of antimicrobial and anticancer peptides","volume":"332","author":"Dennison","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1125","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115360_bb1130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115360_bb1135","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1140","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb1145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/10600280211058388","article-title":"Pepaxto: a new peptide-drug conjugate for heavily pretreated relapsed and refractory multiple myeloma","volume":"56","author":"Jessee","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115360_bb1150","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065700","article-title":"Assessment of the pharmacokinetics, disposition, and duration of action of the tumour-targeting peptide CEND-1","volume":"24","author":"Jarvelainen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb1165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S2468-1253(22)00197-2","article-title":"CEND-1: a game changer for pancreatic cancer chemotherapy?","volume":"7","author":"Springfeld","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-106094","article-title":"LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme","volume":"15","author":"Truusalu","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2026.115360_bb1175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cpdd.1502","article-title":"Population pharmacokinetic modeling of Certepetide in human subjects with metastatic pancreatic ductal adenocarcinoma","volume":"14","author":"Winning","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jconrel.2026.115360_bb1180","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nchembio.184","article-title":"Phage-encoded combinatorial chemical libraries based on bicyclic peptides","volume":"5","author":"Heinis","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1185","doi-asserted-by":"crossref","first-page":"12690","DOI":"10.1002\/chem.201702117","article-title":"Bicyclic peptides as next-generation therapeutics","volume":"23","author":"Rhodes","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2026.115360_bb1190","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1021\/acs.bioconjchem.5c00524","article-title":"From cloudy to clear: a strategy to resolve the complex structural elucidation of bicycle drug conjugate Zelenectide Pevedotin by NMR","volume":"37","author":"Jonasson","year":"2026","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115360_bb1195","series-title":"NGR-hTNF. Drug News Perspect","first-page":"395","volume":"23","author":"Molecule of the Month","year":"2010"},{"key":"10.1016\/j.jconrel.2026.115360_bb1200","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-013-0048-z","article-title":"Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example","volume":"27","author":"Corti","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2026.115360_bb1205","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/med.20238","article-title":"Targeted drug delivery and penetration into solid tumors","volume":"32","author":"Corti","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2026.115360_bb1210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjc.6605162","article-title":"Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours","volume":"101","author":"Gregorc","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb1215","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bjc.6605858","article-title":"Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma","volume":"103","author":"Santoro","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb1220","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.ejca.2010.07.012","article-title":"Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy","volume":"46","author":"Santoro","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb1225","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-09-1621","article-title":"Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)","volume":"16","author":"van Laarhoven","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb1230","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/1078-0432.CCR-10-1376","article-title":"Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors","volume":"17","author":"Gregorc","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb1235","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdq436","article-title":"Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies","volume":"22","author":"Mammoliti","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.2012.233","article-title":"Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients","volume":"107","author":"Lorusso","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115360_bb1245","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.molmed.2008.06.003","article-title":"The moonlighting enzyme CD13: old and new functions to target","volume":"14","author":"Mina-Osorio","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184511","article-title":"Mechanism of action of the tumor vessel targeting agent NGR-hTNF: role of both NGR peptide and hTNF in cell binding and signaling","volume":"20","author":"Valentinis","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115360_bb1255","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri3834","article-title":"Regulation of tumour necrosis factor signalling: live or let die","volume":"15","author":"Brenner","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1260","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.115360_bb1265","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1244","article-title":"Boolean logic in synthetic biology and biomaterials: towards living materials in mammalian cell therapeutics","volume":"13","author":"Bressler","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115360_bb1270","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14712598.2014.920814","article-title":"Probody therapeutics for targeting antibodies to diseased tissue","volume":"14","author":"Polu","year":"2014","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb1275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14712598.2020.1699053","article-title":"Antibody prodrugs for cancer","volume":"20","author":"Kavanaugh","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115360_bb1280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115360_bb1285","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biochi.2015.11.003","article-title":"In vivo imaging of protease activity by probody therapeutic activation","volume":"122","author":"Wong","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.jconrel.2026.115360_bb1290","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in Immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115360_bb1295","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115360_bb1300","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature01511","article-title":"Mass spectrometry-based proteomics","volume":"422","author":"Aebersold","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115360_bb1305","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1074\/mcp.R800002-MCP200","article-title":"Proteomic contributions to personalized cancer care","volume":"7","author":"Koomen","year":"2008","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jconrel.2026.115360_bb1310","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.soc.2023.12.004","article-title":"Evolution of precision oncology, personalized medicine, and molecular tumor boards","volume":"33","author":"Fujiwara","year":"2024","journal-title":"Surg. Oncol. Clin. N. Am."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:19:30Z","timestamp":1793337570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":262,"alternative-id":["S0168365926007649"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115360","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-homing peptides in precision oncology","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115360"}}